CS Medica Past Earnings Performance

Past criteria checks 0/6

CS Medica's earnings have been declining at an average annual rate of -44%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 23.3% per year.

Key information

-44.0%

Earnings growth rate

-40.6%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate23.3%
Return on equity-160.4%
Net Margin-114.1%
Next Earnings Update10 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CS Medica makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:8G8 Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248-10140
30 Jun 245-12140
31 Mar 245-13160
31 Dec 233-14160
30 Sep 231-15170
30 Jun 2310-11160
31 Mar 2311-11170
31 Dec 2211-12180
30 Sep 2211-11170
30 Jun 224-10140
31 Mar 223-590
31 Dec 213-250
30 Sep 213120
30 Jun 211020
30 Sep 202010
30 Sep 191000

Quality Earnings: 8G8 is currently unprofitable.

Growing Profit Margin: 8G8 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8G8 is unprofitable, and losses have increased over the past 5 years at a rate of 44% per year.

Accelerating Growth: Unable to compare 8G8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8G8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 8G8 has a negative Return on Equity (-160.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:19
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CS Medica A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christian SandherrNuWays AG